Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal Δ9-tetrahydrocannabinol

European Journal of Pharmacology

Volumn 525, Issue 1-3, 2005, Pages 74-82

  Cichewicz, Diana L ^a   Welch, Sandra P ^b   Smith, Forrest L ^b  

^a Philip Morris USA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

9 THC; (Guinea pig); Antinociception; Buprenorphine; Fentanyl; Transdermal

Indexed keywords

BUPRENORPHINE; DIETHYLENE GLYCOL MONOETHYL ETHER; DRONABINOL; FENTANYL; FENTANYL CITRATE;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; EXPERIMENTAL MODEL; FEMALE; GUINEA PIG; LOW DRUG DOSE; NONHUMAN; PRICK TEST; PRIORITY JOURNAL;

ADMINISTRATION, CUTANEOUS; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; DRUG SYNERGISM; FEMALE; FENTANYL; GUINEA PIGS; PAIN MEASUREMENT; TETRAHYDROCANNABINOL;

EID: 28044445123     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.09.039     Document Type: Article

References (33)

1. L. Allan, H. Hays, N.-H. Jensen, B. Le Polain de Waroux, M. Bolt, R. Donald, and E. Kalso Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain Brit. Med. J. 322 2001 1 7
2. A.R. Blight, M.E. McGinnis, and R.B. Borgens Cutaneus trunci muscle reflex of the guinea pig J. Comp. Neurol. 296 1990 614 633
3. C.I. Bliss Statistics in Biology 1967 McGraw-Hill New York, NY 439
4. R.A. Boas, and J.W. Villiger Clinical actions of fentanyl and buprenorphine. The significance of receptor binding Br. J. Anaesth. 57 1985 192 196
5. R.A. Caplan, and M. Southam Transdermal drug delivery and its application to pain control C. Benedetti Advances in Pain Research and Therapy 1990 Raven Press New York, NY 233 240
6. D.L. Cichewicz Synergistic interactions between cannabinoid and opioid analgesics Life Sci. 74 2004 1317 1324
7. D.L. Cichewicz, and E.A. McCarthy Antinociceptive synergy between delta(9)-tetrahydro-cannabinol and opioids after oral administration J. Pharmacol. Exp. Ther. 304 2003 1010 1015
8. D.L. Cichewicz, Z.L. Martin, F.L. Smith, and S.P. Welch Enhancement of mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification J. Pharmacol. Exp. Ther. 289 1999 859 867
9. D. Colquhoun Lectures on Biostatistics: An Introduction to Statistics with Applications in Biology and Medicine 1971 Clarendon Press Oxford, U.K. 327 333
10. J. De Castro, J. Meynadier, and M. Zanz Drugs J. de Castro J. Meynadier M. Zanz Regional Opioid Analgesia 1991 Klumer Academic Publishers Dordrecht 131 209
11. B. Donner, and M. Zenz Transdermal fentanyl: a new step on the therapeutic ladder Anticancer Drugs 6 1995 39 43
12. H.C. Evans, and S.E. Easthope Transdermal buprenorphine Drugs 63 2003 1999 2012
13. D.B. Gilbert, S.L. Motzel, and S.R. Das Postoperative pain management using fentanyi patches in dogs Contemp. Top. Lab. Anim. Sci. 42 2003 21 26
14. G.K. Gourlay, S.R. Kowalski, J.L. Plummer, D.A. Cherry, P. Gaukroger, and M.J. Cousins The transdermal administration of fentanyi in the treatment of postoperative pain: pharmacokinetics and pharmacodynamic effects Pain 37 1989 193 202
15. B.C. Hains, K.M. Chastain, A.W. Everhart, D.J. McAdoo, and C.E. Hulsebosch Transplants of adrenal medullary chromaffin cells reduce forelimb and hindlimb allodynia in a rodent model of chronic central pain after spinal cord hemisection injury Exp. Neural. 164 2000 426 437
16. B.B. Hayes, A. Afshari, L. Millecchia, P.A. Willard, S.P. Povoski, and B.J. Meade Evaluation of percutaneous penetration of natural rubber latex proteins Toxicol. Sci. 56 2000 262 270
17. R.C. Heel, R.N. Brogden, T.M. Speight, and G.S. Avery Buprenorphine: a review of its pharmacological properties and therapeutic efficacy Drugs 17 1979 81 110
18. A.B. Khodorova, and G.R. Strichartz The addition of dilute epinephrine produces equieffectiveness of bupivacaine enantiomers for cutaneous analgesia in the rat Anesth. Analg. 91 2000 410 416
19. S. Kramer, I. Nolte, and W. Jochle Clinical comparison of medetomidine with xylazine/l-methadone in dogs Vet. Rec. 138 1996 128 133
20. J.D. Leander Buprenorphine is a potent/cappa-opioid receptor antagonist in pigeons and mice Eur. J. Pharmacol. 151 1988 457 461
21. W. Ling, C. Charuvastra, J.F. Collins, S. Batki, L.S. Brown Jr., P. Kintaudi, D.R. Wesson, L. McNicholas, D.J. Tusel, U. Malkemeker, J.A. Renner Jr., E. Santos, P. Casadonte, C. Fye, S. Stine, R.I. Wang, and D. Segal Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial Addiction 93 1998 475 486
22. R.Z. Litten, and J.P. Allen Medications for alcohol, illicit drug, and tobacco dependence. An update of research findings J. Subst. Abuse Treat. 16 1999 105 112
23. D.J. Mason Jr., J. Lowe, and S.P. Welch Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception Eur. J. Pharmacol. 378 1999 237 248
24. N.K. Mello, J.H. Mendelson, S.E. Lukas, D.R. Gastfriend, S.K. Teoh, and B.L. Holman Buprenorphine treatment of opiate and cocaine abuse: clinical and preclinical studies Harv. Rev. Psychiatry. 1 1993 168 183
25. H. Miyauchi, and T. Horio A new animal model for contact dermatitis: the hairless guinea pig J. Dermatol. 19 1992 140 145
26. T.J. Morrow, and K.L. Casey Suppression of bulboreticular unit responses to noxious stimuli by analgesic mesencephalic stimulation Somatosens. Res. 1 1983 151 168
27. R. Payne, S.D. Mathias, D.J. Pasta, L.A. Wanke, R. Williams, and R. Mahmoud Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine J. Clin. Oncol. 16 1998 1588 1593
28. R. Sittl, N. Griessinger, and R. Likar Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial Clin. Ther. 25 2003 150 168
29. F.L. Smith, D. Cichewicz, Z.L. Martin, and S.P. Welch The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol Pharmacol. Biochem. Behav. 60 1998 559 566
30. A.L. Stinchcomb, R. Dua, A. Paliwal, R.W. Woodard, and G.L. Flynn A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters Pharm. Res. 12 1995 1526 1529
31. O. Valverde, F. Noble, F. Beslot, V. Dauge, M.C. Foumie-Zaluski, and B.P. Roques Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect Eur. J. Neurosci. 13 2001 1816 1824
32. S.P. Welch, and M. Eads Synergistic interactions of endogenous opioids and cannabinoid systems Brain Res. 848 1999 183 190
33. O. Yesilyurt, A. Dogrul, H. Gul, M. Seyrek, O. Kusmez, Y. Ozkan, and O. Yildiz Topical cannabinoid enhances topical morphine antinociception Pain 105 2003 303 308